A “vicious cycle” of NK-cell immune evasion in acute myeloid leukemia mediated by RANKL?

Receptor activator of NFκB ligand (RANKL) is mainly known for its role in bone metabolism, constituting a target for therapeutic interventions. Increasing evidence suggests that RANKL is also involved in oncogenesis and tumor progression, including a prominent role in host-tumor interaction. Our dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmiedel, Benjamin Joachim, Grosse-Hovest, Ludger, Salih, Helmut Rainer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667891/
https://www.ncbi.nlm.nih.gov/pubmed/23762785
http://dx.doi.org/10.4161/onci.23850
Descripción
Sumario:Receptor activator of NFκB ligand (RANKL) is mainly known for its role in bone metabolism, constituting a target for therapeutic interventions. Increasing evidence suggests that RANKL is also involved in oncogenesis and tumor progression, including a prominent role in host-tumor interaction. Our data suggest that targeting RANKL may reinforce natural killer (NK) cell-mediated antitumor responses in patients affected by hematological malignancies.

Ejemplares similares